These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 24395542)

  • 1. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: The centralization of the priming of IV tubing in the pharmacy and use of a closed-system transfer device.
    Guillemette A; Langlois H; Voisine M; Merger D; Therrien R; Mercier G; Lebel D; Bussières JF
    J Oncol Pharm Pract; 2014 Dec; 20(6):426-32. PubMed ID: 24395542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of surface contamination in a hospital hematology--oncology pharmacy.
    Touzin K; Bussières JF; Langlois E; Lefebvre M
    J Oncol Pharm Pract; 2009 Mar; 15(1):53-61. PubMed ID: 18772214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 66 Canadian hospitals: A 2016 follow-up study.
    Roland C; Caron N; Bussières JF
    J Occup Environ Hyg; 2017 Aug; 14(8):661-669. PubMed ID: 28574754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: a 2013 follow-up study.
    Berruyer M; Tanguay C; Caron NJ; Lefebvre M; Bussières JF
    J Occup Environ Hyg; 2015; 12(2):87-94. PubMed ID: 25105559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device.
    Sessink PJ; Connor TH; Jorgenson JA; Tyler TG
    J Oncol Pharm Pract; 2011 Mar; 17(1):39-48. PubMed ID: 20156932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing workplace cytotoxic surface contamination using a closed-system drug transfer device.
    Siderov J; Kirsa S; McLauchlan R
    J Oncol Pharm Pract; 2010 Mar; 16(1):19-25. PubMed ID: 19965949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Environmental contamination with methotrexate in Canadian community pharmacies.
    Merger D; Tanguay C; Langlois É; Lefebvre M; Bussières JF
    J Am Pharm Assoc (2003); 2013; 53(4):423-6. PubMed ID: 23892817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Closed-system drug-transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional hazardous drugs in healthcare staff.
    Gurusamy KS; Best LM; Tanguay C; Lennan E; Korva M; Bussières JF
    Cochrane Database Syst Rev; 2018 Mar; 3(3):CD012860. PubMed ID: 29582940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre and post intervention study of antiblastic drugs contamination surface levels at a Pharmacy Department Compounding Area using a closed system drug transfer device and a decontamination process.
    Valero S; López-Briz E; Vila N; Solana A; Melero M; Poveda JL
    Regul Toxicol Pharmacol; 2018 Jun; 95():1-7. PubMed ID: 29510165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot assessment of the antineoplastic drug contamination levels in British Columbian hospitals pre- and post-cleaning.
    Chu WC; Hon CY; Danyluk Q; Chua PP; Astrakianakis G
    J Oncol Pharm Pract; 2012 Mar; 18(1):46-51. PubMed ID: 21737485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter evaluation of a new closed system drug-transfer device in reducing surface contamination by antineoplastic hazardous drugs.
    Bartel SB; Tyler TG; Power LA
    Am J Health Syst Pharm; 2018 Feb; 75(4):199-211. PubMed ID: 29339374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals.
    Poupeau C; Tanguay C; Caron NJ; Bussières JF
    J Oncol Pharm Pract; 2018 Jan; 24(1):9-17. PubMed ID: 27799608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter study of environmental contamination with antineoplastic drugs in 33 Canadian hospitals.
    Merger D; Tanguay C; Langlois E; Lefebvre M; Bussières JF
    Int Arch Occup Environ Health; 2014 Apr; 87(3):307-13. PubMed ID: 23471647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of a closed system drug-transfer device eliminates surface contamination with antineoplastic agents.
    Clark BA; Sessink PJ
    J Oncol Pharm Pract; 2013 Jun; 19(2):99-104. PubMed ID: 23292973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Environmental contamination, product contamination and workers exposure using a robotic system for antineoplastic drug preparation.
    Sessink PJ; Leclercq GM; Wouters DM; Halbardier L; Hammad C; Kassoul N
    J Oncol Pharm Pract; 2015 Apr; 21(2):118-27. PubMed ID: 24567041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Closed-system Transfer Devices in Reducing Potential Risk for Surface Contamination Following Simulated Hazardous-drug Preparation and Compounding.
    Soefje S; Rickabaugh K; Rajkumar R; Wall KP
    Int J Pharm Compd; 2021; 25(6):515-522. PubMed ID: 34807847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Closed-system Transfer Devices in Reducing Potential Risk for Surface Contamination Following Simulated Hazardous-drug Preparation and Compounding.
    Soefje S; Rickabaugh K; Rajkumar R; Wall KP
    Int J Pharm Compd; 2022; 26(1):72-79. PubMed ID: 35081047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of healthcare workers' exposure to cyclophosphamide, ifosfamide, methotrexate, and 5-fluorouracil by 24-h urine assay: A descriptive pilot study.
    Palamini M; Dufour A; Therrien R; Delisle JF; Mercier G; Gagné S; Caron N; Bussières JF
    J Oncol Pharm Pract; 2020 Dec; 26(8):1864-1870. PubMed ID: 32138611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers.
    Sessink PJ; Boer KA; Scheefhals AP; Anzion RB; Bos RP
    Int Arch Occup Environ Health; 1992; 64(2):105-12. PubMed ID: 1399019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents.
    Wick C; Slawson MH; Jorgenson JA; Tyler LS
    Am J Health Syst Pharm; 2003 Nov; 60(22):2314-20. PubMed ID: 14652980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.